# US 2019/0167571 A1 · Intravenous administration of tramadol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167571 A1
- Document ID: US20190167571A1
- Status: Published application
- Kind: A1
- Application number: 16/269,213
- Filed: 2019-02-06
- Published: 2019-06-06
- Earliest claimed: 2015-12-22
- Assignees: Revogenex Ireland Ltd
- Applicants: Revogenex Ireland Ltd
- Inventors: Lucy Lu; Scott Reines; Jeffrey Ping
- Web page: https://patentgrep.com/patent/US20190167571A1

## CPC

- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/138: Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine (atenolol A61K31/165; pindolol A61K31/404; timolol A61K31/5377)
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously in a dosing regimen which includes one or more loading doses administered at shortened intervals as compared to dosing at steady-state is disclosed. In certain embodiments, the dose of tramadol is from about 45 mg to about 80 mg and the second (and optionally) third doses are intravenously administered at intervals of from about 2 to about 3 hours, and thereafter the tramadol is intravenously administered at a dosing interval of about 4 to about 6 hours, until the patient no longer requires treatment with tramadol. In preferred embodiments, the intravenous dosing regimen provides a Cmax and AUC of tramadol is similar to the Cmax and AUC of an oral dose of 100 mg tramadol HCl given every 6 hours. In certain preferred embodiments, the dosing regimen comprises 50 mg IV tramadol at Hour 0, followed by 50 mg at Hour 2, 50 mg at hour 4, and 50 mg every 4 hours thereafter (e.g., until the patient no longer requires treatment with tramadol).

## Claims

### Claim at position 1

1-15. (canceled)

### Claim 16

A method of administering tramadol for treating acute pain in a human patient(s) via an intravenous dosing regimen, comprising
intravenously administering a first dose of tramadol to a human patient(s) experiencing acute pain in an amount of about 60 mg;
and thereafter intravenously administering additional doses of tramadol to the human patient(s) in an amount of about 60 mg tramadol at dosage intervals of about 6 hours, except that a second dose is intravenously administered as a loading dose at a shortened interval as compared to the dosage interval of about 6 hours, such that a total of 5 doses of 60 mg tramadol are intravenously administered on the first day of treatment and the intravenous tramadol is administered on subsequent days of treatment on a basis of a total of 4 doses of 60 mg tramadol per day until the intravenous tramadol administration is terminated, and wherein the tramadol is tramadol base or a pharmaceutically acceptable salt of tramadol, such that the intravenous dosing regimen provides a steady-state Cmax of tramadol which is similar to the steady-state Cmax of 100 mg tramadol HCl given every 6 hours, and administering another analgesic before, concurrently with, or after administration of the tramadol, thereby treating the acute pain in the subject.

### Claim 17 (depends on 16)

The method of claim 16, wherein the another analgesic is selected from the group consisting of an NSAID, acetaminophen, another opioid analgesic, and a combination of any of the foregoing.

### Claim 18 (depends on 16)

The method of claim 16, wherein the another analgesic is acetaminophen.

### Claim 19 (depends on 16)

The method of claim 16, continuing to administer additional doses of tramadol to the human patient in an amount of about 60 mg tramadol at dosage intervals of about 6 hours for at least about 44 hours after the first administered dose of tramadol.

### Claim 20 (depends on 16)

The method of claim 16, further comprising administering the second dose such that the Cmax and Cmin levels obtained during the initial 24 hour dosing interval are similar to the Cmax and Cmin levels obtained during the initial 24 hour dosing interval for a 100 mg immediate release oral tramadol dose given every 6 hours, but not significantly greater than the steady-state Cmax level for a 100 mg immediate release oral tramadol dose given every 6 hours.

### Claim 21 (depends on 16)

The method of claim 16, wherein the second dose is administered at from about 2 to about 3 hours after the first dose.

### Claim 22

A method of administering tramadol for treating acute postoperative pain in a human patient(s) via an intravenous dosing regimen, comprising
intravenously administering a first dose of tramadol to a human patient(s) experiencing acute pain in an amount of about 60 mg;
and thereafter intravenously administering additional doses of tramadol to the human patient(s) in an amount of about 60 mg tramadol at dosage intervals of about 6 hours, except that a second dose is intravenously administered as a loading dose at a shortened interval as compared to the dosage interval of about 6 hours, such that a total of 5 doses of 60 mg tramadol are intravenously administered on the first day of treatment and the intravenous tramadol is administered on subsequent days of treatment on a basis of a total of 4 doses of 60 mg tramadol per day until the intravenous tramadol administration is terminated, and wherein the tramadol is tramadol base or a pharmaceutically acceptable salt of tramadol, the dosing regimen providing a plasma level of tramadol which is similar to but does not substantially exceed the maximum (Cmax) plasma levels of tramadol obtained at steady-state by a 100 mg oral tramadol dose given every 6 hours prior to the end of the initial 24 hours of intravenous tramadol administration, and administering another analgesic selected from the group consisting of an NSAID, acetaminophen, another opioid analgesic, and any combination thereof before, concurrently with, or after administration of the tramadol, thereby treating the acute pain in the subject.

### Claim 23 (depends on 22)

The method of claim 22, wherein the another analgesic is acetaminophen.

### Claim 24 (depends on 22)

The method of claim 22, wherein the another analgesic is an NSAID.

### Claim 25 (depends on 22)

The method of claim 22, further comprising continuing to administer additional doses of tramadol to the human patient in an amount of about 60 mg tramadol at dosage intervals of about 6 hours for at least about 44 hours after the first administered dose of tramadol.

### Claim 26 (depends on 22)

The method of claim 22, further comprising continuing to administer additional doses of tramadol to the human patient in an amount of about 60 mg tramadol at dosage intervals of about 6 hours for at least about 44 hours after the first administered dose of tramadol, such that the intravenous dosing regimen provides a Cmax of tramadol at steady-state of about 736 ng/mL±152.

### Claim 27

A method of administering tramadol for treating acute postoperative pain in a human patient(s) via an intravenous dosing regimen, comprising
intravenously administering a first dose of tramadol to a human patient(s) experiencing acute pain in an amount of about 60 mg;
and thereafter intravenously administering additional doses of tramadol to the human patient(s) in an amount of about 60 mg tramadol at dosage intervals of about 6 hours, except that a second dose is intravenously administered as a loading dose at a shortened interval as compared to the dosage interval of about 6 hours, such that a total of 5 doses of 60 mg tramadol are intravenously administered on the first day of treatment and the intravenous tramadol is administered on subsequent days of treatment on a basis of a total of 4 doses of 60 mg tramadol per day until the intravenous tramadol administration is terminated, and wherein the tramadol is tramadol base or a pharmaceutically acceptable salt of tramadol, such that the Cmax of the intravenous dosing regimen does not substantially exceed the concentration provided by 100 mg oral tramadol administered every 6 hours at steady-state by more than 15%, and administering another analgesic selected from the group consisting of an NSAID, acetaminophen, another opioid analgesic, and any combination thereof before, concurrently with, or after administration of the tramadol, thereby treating the acute pain in the subject.

### Claim 28 (depends on 29)

The method of claim 29, wherein the another analgesic is acetaminophen.

### Claim 29 (depends on 29)

The method of claim 29, wherein the second dose is administered at from about 2 to about 3 hours after the first dose.

### Claim 30 (depends on 29)

The method of claim 29, wherein the another analgesic is an NSAID.
